“…At the beginning of the pandemic, many trials were forced to close abruptly, experiments were discarded, laboratories were temporarily shut down, and investigators became hesitant to start long term studies due to the fear of potential lockdowns. 1 , 2 As of August, 2020, there remained a 20% decline from pre-COVID baseline in new patients entering cardiovascular trials, although this number is significantly improved from the 97% decline as reported in April 2020. 3 Recovery continues to vary greatly by geographic region and the research environment due to the varying impact of the disease as well as the local policies and responses that have adapted over time.…”